ClinicalTrials.gg
Sign In
CompletedNCT01248247Updated Jan 12, 2022Results posted

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

A Phase 2 interventional study of Erlotinib and AZD6244 in Lung Cancer, sponsored by M.D. Anderson Cancer Center. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-12.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Different people have different biomarkers (chemical "markers" in the blood that may be related to your reaction to study drugs). If researchers know about your biomarkers before you receive treatment, they may be able to prescribe a treatment that is better suited to your body's specific needs.

The goal of this clinical research study is to learn if drug or drug combinations based on your biomarkers can help to control NSCLC. The safety of these drug combinations will also be studied.

Read the detailed description

The Study Drugs:

Erlotinib hydrochloride, MK-2206, AZD6244, and Sorafenib are targeted therapies. Targeted therapy is a type of drug that blocks the growth of cancer cells by interfering with specific targeted molecules needed for tumor growth, rather than by simply interfering with rapidly dividing cells (for example with traditional chemotherapy).

Study Groups:

If you are found to be eligible to take part in this study, you will be assigned to 1 of 4 groups:

  • If you are in Group 1, you will take erlotinib alone.
  • If you are in Group 2, you will take erlotinib and MK-2206.
  • If you are in Group 3, you will take AZD6244 and MK-2206.
  • If you are in Group 4, you will take sorafenib alone.

The group you are in will be assigned by a computer. The results of your screening tests will be used to determine (and may limit) which of the 4 groups you may be eligible to be assigned to. Your likelihood of being in any 1 group over another may also be affected by how well that treatment has done in earlier study participants. Your study doctor will tell you which group you have been assigned.

Study Drug Administration:

Each cycle is 28 days.

  • If you are in Group 1, you will take erlotinib hydrochloride by mouth 1 time every day.
  • If you are in Group 2, you will take MK-2206 by mouth 1 time every week. You will take erlotinib hydrochloride by mouth 1 time every day.
  • If you are in Group 3, you will take MK-2206 by mouth 1 time per week. You will take AZD6244 by mouth 1 time every day.
  • If you are in Group 4, you will take sorafenib by mouth 2 times every day.

If you will take erlotinib hydrochloride (Groups 1 and 2), you should take the tablets in the morning. You should take the drug 1 hour before or 2 hours after a meal, with no more than 7 ounces of water. If you forget to take a dose, the last missed dose should be taken as soon as you remember, as long as it is at least 12 hours before the next dose. The next day, you should take the scheduled dose at the usual time. You should try not to vomit for at least 30 minutes after taking the drug. If you feel nauseated before or after taking the erlotinib, you should take an anti-nausea drug. You may take an extra dose of erlotinib if you vomit within 30 minutes after taking the tablet.

If you are in Group 2, you should take MK-2206 at about the same time each week with about 1 cup (8 ounces) of water. You must take MK-2206 at least 2 hours before or at least 2 hours after any food or a meal. You should not make up any missed doses.

If you are in Group 3, you should take MK-2206 at about the same time each week with about 1 cup (8 ounces) of water. You must take MK-2206 at least 2 hours before or at least 2 hours after eating. You should not make up any missed doses.

If you will take AZD6244 (Group 3), you should take the study drug in the morning before you eat or drink anything. You can eat breakfast 1 hour after you take the dose.

If you will take sorafenib, you must take your doses 12 hours apart. You will take 2 tablets each morning, and again each evening. Sorafenib should be taken with about 1 cup of water on an empty stomach (either 1 hour before a meal or 2 hours after a meal). If you feel nauseated before or after taking the medication, anti-nausea medications should be used. If you miss a dose, you should skip it and take the next scheduled dose at the right time.

Your medication should be stored at room temperature.

Study Visits:

The study visit schedule is described below. In certain cases, with the permission of your doctor, the study visits may occur up to 7 days earlier or later than described below.

On Day 1 of each cycle:

  • You will have a complete physical exam, including measurement of your weight and vital signs.
  • You will be asked about any drugs you may be taking and any side effects you may be having.
  • Your performance status will be recorded.
  • Blood (about 3 teaspoons) will be drawn for routine tests. If your doctor thinks it is needed, you may have to have these blood tests more often.

On Day 1 of every odd-numbered cycle (Cycles 3, 5, 7, and so on):

  • You will have a CT scan and/or MRI of the chest (and abdomen if the doctor thinks it is needed) to check the status of the disease.
  • You will have a chest x-ray.
  • MRI of the brain (if the doctor thinks it is needed)

Additional Tests for Group 2:

  • During screening, on Day 1 of Cycle 2, and at the end-of study visit, you will have an eye exam.
  • On Day 1 of Cycle 1 you will have an ECG before taking your study medication and then again about 4 hours after you take your study medication.

Additional Tests for Group 3:

  • During screening, on Day 1 of Cycle 2, and at the end-of study visit, you will have an eye exam.
  • During Cycle 2 (Week 6 of being on study drug), on Day 1 of Cycle 4, and then every 3 months, you will have a multigated acquisition (MUGA) scan and/or echocardiogram to check your heart function. You will have these tests more often if the doctor thinks it is needed.
  • On Day 1 of Cycle 1 you will have an ECG before taking your study medication and then again about 4 hours after you take your study medication.

Length of Study:

You may continue to take the study drug(s) for as long as you are benefitting. You will be taken off study if the disease gets worse or if you have intolerable side effects.

End-of-Study Visit:

When you go off study for any reason, you will have an end-of-study. This visit may occur up to 7 days earlier or later. The following tests and procedures will be performed:

  • Your medical history will be recorded.
  • You will have a complete physical exam, including measurement of your weight and vital signs.
  • You will be asked about any drugs you may be taking and any side effects you may be having.
  • Your performance status will be recorded.
  • Blood (about 3 teaspoons) and urine will be collected for routine tests.
  • You will have a CT scan and/or MRI of the chest (and abdomen if the doctor thinks it is needed) to check the status of the disease.
  • You will have a chest x-ray.
  • You will have an ECG (Group 3).

Follow-Up:

You will have a follow-up evaluation performed 4 weeks ± 7 days after therapy is discontinued. This evaluation may be a visit or contact by phone by the research personnel. If you are in Group 3, you will have a MUGA scan and/or echocardiogram to check your heart function.

You will be called every 3 months for up to 3 years and asked about any cancer treatments you may be receiving. This phone call will take about 10 minutes.

This is an investigational study. Erlotinib is FDA approved and commercially available for treatment of NSCLC that has gotten worse. Sorafenib is approved in renal cell cancer and hepatocellular carcinoma. Sorafenib has also has also been evaluated in unselected advanced patients with NSCLC both alone or with chemotherapy in the first-time treatment of patients . MK-2206, and AZD6244 are not FDA-approved or commercially available. At this time, they are only being used in research.

Up to 450 patients will take part in this multicenter study. Approximately 350 will be enrolled at MD Anderson.

02

Conditions studied

  • Lung Cancer

Keywords

  • Non small cell lung cancer
  • Biopsy accessible tumor
  • Stage IIIB non small cell lung cancer
  • Stage IV non small cell lung cancer
03

In context

Lung Neoplasms

7,333 studies on the registry are indexed under Lung Neoplasms; 1,554 are open to participants now.

This study's enrollment of 334 is above the median of 60 across 5,345 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,044 studies on the registry; 578 are open to participants now.

Of its 608 completed or terminated interventional studies of FDA-regulated products, 407 (67%) have results posted.

Browse M.D. Anderson Cancer Center studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject has a diagnosis of pathologically confirmed NSCLC by tumor biopsy and/or fine-needle aspiration.
  2. The subject has a diagnosis of either advanced, incurable stage IIIB or stage IV NSCLC, and failed at least one front-line metastatic NSCLC chemotherapy regimen, or EGFR TKI. (Subjects who have failed adjuvant or locally advanced therapy within 6 months are also eligible to participate in the study).
  3. The subject has measurable NSCLC (patients with active new disease growth in previously irradiated site are eligible).
  4. The subject's ECOG performance status is \</= 2 at study entry.
  5. The subject has biopsy accessible tumor
  6. The subject has adequate hematologic function as defined by an absolute neutrophil count (ANC) >/= 1,500/mm3, platelet count >/= 100,000/mm3, WBC >/= 3,000/ mm3, and hemoglobin >/= 9 g/dL.
  7. The subject has adequate hepatic function as defined by a total bilirubin level \</= 1.5 x the upper limit of normal (ULN) (bilirubin >/= 1.5 x ULN with known Gilbert's disease is allowed), and alkaline phosphatase, AST and ALT \</= 2.5 x the upper limit of normal or \</= 5.0 x ULN if liver metastases are present.
  8. Serum creatinine clearance >50ml/min, either by Cockcroft-Gault formula or 24-hour urine collection analysis
  9. If subject has brain metastasis, they must have been stable (treated and/or asymptomatic) and off steroids for at least 2 weeks.
  10. The subject is >/=18 years of age.
  11. The subject has signed informed consent.
  12. The subject is eligible if disease free from a previously treated malignancy, other than a previous NSCLC, for greater than two years. Subject with a history of prior basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix are allowed.
  13. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Childbearing potential will be defined as women who have had menses within the past 12 months, who have not had tubal ligation, hysterectomy or bilateral oophorectomy. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately.
  14. The subject, if a man, agrees to use effective contraception or abstinence while on study and for 90 days after last dose of study drug.
  15. Subject is able to swallow capsules and has no surgical or anatomical condition that will preclude the patient from swallowing and absorbing oral medications on an ongoing basis.

Exclusion criteria

Exclusion Criteria:

  1. The subject has received prior chemotherapy, surgery, or radiotherapy within 3 weeks of initiating study drug, or 4 weeks for bevacizumab or investigational drug or 72 hours for erlotinib or the subject has not recovered (\</= Grade 1) from side effects of the prior therapy (localized palliative radiotherapy within 2 weeks is allowed).
  2. The subject has undergone prior thoracic or abdominal surgery within 30 days of study entry, excluding prior diagnostic biopsy.
  3. The subject has cardiac conditions as follows: uncontrolled hypertension BP > 140/90 despite optimal therapy, uncontrolled angina, ventricular arrhythmias, or congestive heart failure New York Heart Association Class II or above, baseline LVEF \</= 50%, prior or current cardiomyopathy, atrial fibrillation with heart rate >100 bpm, unstable ischaemic heart disease (MI within 6 months prior to starting treatment, or angina requiring use of nitrates more than once weekly).
  4. The subject has neuropathy >/= grade 2
  5. The subject is pregnant (confirmed by serum b-HCG if applicable) or is breastfeeding. In the event of inconclusive pregnancy test results, the investigator will have final determination of pregnancy status.
  6. Subjects will be excluded for other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, severe infection requiring active treatment, severe malnutrition, chronic severe liver or renal disease).
  7. Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption
  8. Subjects with poorly controlled diabetes (HbA1c >8%) are excluded.
  9. Subjects whose tumor harbors the EML4-ALK fusion gene are excluded unless the patient has failed treatment with Anaplastic Lymphoma Kinase (ALK) inhibitor.
  10. Subjects are excluded if they have QTc prolongation >450 msec (Bazett's Formula) for males or >470 ms for females on screening or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) including heart failure that meets New York Heart Association (NYHA) class II or above or require use of a concomitant medication that can prolong the QT interval.
  11. Subjects who have abnormal K+ or Mg++ levels will be excluded if these levels cannot be corrected to within normal range with adequate supportive treatment prior to study drug initiation.
  12. Subjects whose tumor harbors an EGFR mutation are excluded unless the subject failed treatment with EGFR TKIs in which case the subject can be randomized to Arms 2, 3, and 4.
  13. Drug Specific Eligibility Criteria based on Treatment Arms- Subjects are excluded from the erlotinib monotherapy arm if they have progressed on prior EGFR TKI therapy; from the AKT inhibitor arm(s) if they have received prior AKT inhibitor therapy; from the MEK inhibitor arm if they have received prior MEK inhibitor therapy; and from Sorafenib arm if they have previously received the drug or have prior history of clinically significant hemoptysis or bleeding diathesis as per principal investigator judgment.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
334 participants (actual)

Study arms

  • Experimental
    Group 1 - Erlotinib

    Erlotinib 150 mg by mouth each day of a 28 day cycle.

    Drug: Erlotinib

  • Experimental
    Group 2 - Erlotinib + MK-2206

    Erlotinib 150 mg by mouth each day of a 28 day cycle. MK-2206 135 mg by mouth every week of a 28 day cycle.

    Drug: Erlotinib · Drug: MK-2206

  • Experimental
    Group 3 - AZD6244 + MK-2206

    AZD6244 100 mg by mouth daily of a 28 day cycle. MK-2206 100 mg by mouth every week of a 28 day cycle.

    Drug: AZD6244 · Drug: MK-2206

  • Experimental
    Group 4 - Sorafenib

    Sorafenib 400 mg by mouth twice a day for a 28 day cycle.

    Drug: Sorafenib

Interventions

  • DrugErlotinib

    150 mg by mouth each day of a 28 day cycle.

    Also known as: OSI-774, Tarceva

  • DrugAZD6244

    100 mg by mouth daily of a 28 day cycle.

  • DrugMK-2206

    100 mg by mouth every week of a 28 day cycle.

  • DrugSorafenib

    400 mg by mouth twice a day for a 28 day cycle.

    Also known as: Nexavar, BAY43-9006

  • DrugErlotinib

    150 mg by mouth daily of a 28 day cycle.

    Also known as: OSI-774, Tarceva

  • DrugMK-2206

    135 mg by mouth every week of a 28 day cycle.

06

What researchers measure

Primary outcomes

  1. 8-Week Disease Control Rate (DCR)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: 8 weeks

Secondary outcomes

  1. Median Progression-free Survival

    Progression-free survival was estimated by Kaplan-Meier method

    Time frame: From the date of drug start to the earliest sign of disease progression or death

07

Results

Posted Jan 12, 2022

Participant flow

Patients with pretreated NSCLC who agreed to a baseline tumor biopsy, who had ECOG P of 0 to 2, and who had multiple prior lines of therapy and stable or treated brain metastases were enrolled. Patients were excluded if their tumor harbored EGFR sensitizing mutations or ALK gene fusions, and they were erlotinib or crizotinib na¨ıve.

Participant flow — Overall Study
MilestoneArm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - Sorafenib
Started22427561
Completed0000
Not completed22427561
Withdrew: Adverse event2442
Withdrew: Death0147
Withdrew: Lost to follow-up0110
Withdrew: Alternative treatment0100
Withdrew: Other2885
Withdrew: Progression18275644
Withdrew: Refuse further treatment0012
Withdrew: Complicating disease0011

Outcome measures

Primary8-Week Disease Control Rate (DCR)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
8-Week Disease Control Rate (DCR)
ParticipantsArm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - Sorafenib
Partial Response0033
Stable Disease6183425
Progressive Disease13183333
SecondaryMedian Progression-free Survival

Progression-free survival was estimated by Kaplan-Meier method

Time frame:
From the date of drug start to the earliest sign of disease progression or death
Reported as:
Median · months
Median Progression-free Survival
monthsArm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - Sorafenib
Median Progression-free Survival1.8 (1.6 to 3.5)2.5 (1.9 to 3.5)2.2 (1.8 to 3.6)2.1 (1.8 to 2.8)

Adverse events

Collected over From the first dose through 30 days after the last dose of study medication, up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 - Erlotinib19/22 (86.4%)3/22 (13.6%)21/22 (95.5%)
Arm 2 - Erlotinib + MK-220636/42 (85.7%)13/42 (31%)42/42 (100%)
Arm 3 - AZD6244 + MK-220665/75 (86.7%)29/75 (38.7%)75/75 (100%)
Arm 4 - Sorafenib51/61 (83.6%)24/61 (39.3%)61/61 (100%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventArm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - Sorafenib
DyspneaReproductive system and breast disorders1/221/427/755/61
Back painMusculoskeletal and connective tissue disorders0/221/420/754/61
Pleural effusionRespiratory, thoracic and mediastinal disorders0/220/421/754/61
Thromboembolic eventVascular disorders0/220/424/751/61
Lung infectionInfections and infestations1/220/423/753/61
DiarrheaGastrointestinal disorders0/222/420/751/61
FeverGeneral disorders0/222/420/750/61
Respiratory failureRespiratory, thoracic and mediastinal disorders0/222/423/750/61
VomitingGastrointestinal disorders0/222/421/750/61
Multi-organ failureGeneral disorders1/220/420/750/61
Most frequent other events
Showing 10 of 30
Most frequent other events
EventArm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - Sorafenib
DiarrheaGastrointestinal disorders8/2224/4226/7516/61
Rash AcneiformSkin and subcutaneous tissue disorders11/2218/4229/753/61
FatigueGeneral disorders2/2215/4231/7526/61
Rash MaculopapularSkin and subcutaneous tissue disorders3/2214/4229/7524/61
Increased ASTInvestigations5/225/4229/757/61
AnorexiaMetabolism and nutrition disorders6/2216/429/7515/61
Increased alkaline phosphataseInvestigations2/2210/4217/7522/61
VomitingGastrointestinal disorders5/2210/4227/7514/61
NauseaGastrointestinal disorders7/2213/4225/7512/61
HyperglycemiaMetabolism and nutrition disorders2/2211/4224/754/61

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - SorafenibTotal
Median61 (34 to 82)62 (43 to 78)61 (26 to 76)62 (35 to 79)61 (26 to 82)
Age, Customized
Age, Customized(Participants)Arm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - SorafenibTotal
<=49 years226717
Between 50 and 59 years816271970
Between 60 and 69 years1012292475
>=70 years212131138
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - SorafenibTotal
Female10154932106
Male1227262994
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - SorafenibTotal
Hispanic or Latino313714
Not Hispanic or Latino19417254186
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - SorafenibTotal
American Indian or Alaska Native00011
Asian10214
Native Hawaiian or Other Pacific Islander00000
Black or African American326819
White18406751176
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Arm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - SorafenibTotal
United States22427561200
KRAS mut+
KRAS mut+(Participants)Arm 1 - ErlotinibArm 2 - Erlotinib + MK-2206Arm 3 - AZD6244 + MK-2206Arm 4 - SorafenibTotal
No16345343146
Yes68221854
08

Study locations

2 sites
  • Yale Universtiy
    New Haven, Connecticut 06520, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 8, 2019

Documents are hosted by the registry — open the source record to download them.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Nov 2020, 113 months.

Results were first posted in Jan 2022, 1 year 1 month after primary completion.

Of 535 non-industry phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 86. This study's 113 months is above that.

Counting every sponsor, half of 712 studies reached it within 46 months; a quarter within 30 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2010
First posted
Nov 25, 2010
StartActual
Jun 2, 2011
Primary completionActual
Nov 30, 2020
CompletionActual
Nov 30, 2020
Results first posted
Jan 12, 2022
Last update
Jan 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01248247
Lead sponsor
M.D. Anderson Cancer Center
Collaborators
Merck Sharp & Dohme LLC, National Cancer Institute (NCI), GlaxoSmithKline, Novartis
Responsible party
Sponsor
First posted
Nov 25, 2010
Start date
Jun 2, 2011
Primary completion
Nov 30, 2020
Completion
Nov 30, 2020
Results posted
Jan 12, 2022
Last update
Jan 12, 2022

Study contacts

Marcelo V. Negrao, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Erlotinib · AZD 6244 · MK 2206 · Sorafenib

Other studies in this condition

Lung Neoplasms →

Other studies from this sponsor

M.D. Anderson Cancer Center →

Start the discussion